GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity. The rapid increase in global demand for drugs such as semaglutide, liraglutide, and tirzepatide has led to a growing market for unapproved drugs, specially formulated products, and counterfeit drugs.